Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Forbes Has Listed Gilead as One of America's Best Employers for Diversity

Accesswire 1 day ago

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire 4 days ago

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

Business Wire 8 days ago

Gilead Sciences Announces First Quarter 2024 Financial Results

Business Wire 9 days ago

Gilead Sciences Publishes 2023 ESG Impact Report

Accesswire April 18, 2024

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024

Business Wire April 8, 2024

Gilead Sciences Champions Equal Pay

Accesswire April 2, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

Business Wire March 28, 2024

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GlobeNewswire March 28, 2024

Winn Awards Help Physicians Solve Healthcare Disparities

Accesswire March 26, 2024

Gilead Sciences Announces Completion of Acquisition of CymaBay

Business Wire March 22, 2024

Gilead Helps Launch Türkiye's First HIV Testing Week

Accesswire March 19, 2024

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant

Business Wire March 18, 2024

Gilead Science Supports Increasing Diversity in Clinical Trials: 2024 Toward Health Equity Oncology Grant Supports 36 Global Organizations

Accesswire March 12, 2024

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer

Business Wire March 11, 2024

Gilead Sciences Aids in Reducing Cancer Care Disparities: Dale Shares Her Breast Cancer Journey and the Power of Information Sharing

Accesswire March 7, 2024

Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities

Business Wire March 6, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Business Wire March 6, 2024

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Business Wire March 6, 2024

New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19

Business Wire March 5, 2024